Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Phase 2 Unknown

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06195683 2024-01-08

NSCLC

Phase 2 Unknown

23 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04937972 2023-12-29

FLYFLY

Phase 2 Unknown

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05329025 2023-11-24

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05812534 2023-11-18

CBC

Phase 2 Unknown

36 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05311709 2023-11-09

SOLUCOM

Phase 2 Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04467801 2023-11-07

Ipat-Lung

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05863325 2023-11-07

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04726215 2023-09-29

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05128630 2023-09-28

DEDALUS

Phase 2 Unknown

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05338619 2023-09-01

PLATINUM

Phase 2 Unknown

77 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Phase 2 Unknown

129 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05869162 2023-08-25

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Phase 2 Unknown

153 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05892237 2023-08-23

CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2 Unknown

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05900219 2023-06-12

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Phase 2 Unknown

75 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04580498 2023-05-19

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Phase 2 Unknown

107 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04202809 2023-05-10

ESPADURVA

Phase 2 Unknown

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05847764 2023-05-08

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2 Unknown

95 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05813522 2023-04-14

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Phase 2 Unknown

30 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Phase 2 Unknown

40 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05801107 2023-04-06

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04840004 2023-04-05

Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Unknown

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

20 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03975114 2023-03-24

MILES-5

Phase 2 Unknown

460 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04992715 2023-03-22

PELICAN

Phase 2 Unknown

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04338620 2023-03-06

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Phase 2 Unknown

94 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05754736 2023-03-06

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

84 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

KeyPemls-004

POSTILV

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

KICKSTART

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

MELROSE

VUBAR

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

NSCLC

FLYFLY

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

CBC

SOLUCOM

Ipat-Lung

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

ROME

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

DEDALUS

PLATINUM

CHAMELEON

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

ESPADURVA

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

MILES-5

PELICAN

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)